GO
Loading...

Eli Lilly and Co

More

  • Early Glance: Pharmaceuticals companies Tuesday, 12 Aug 2014 | 12:14 PM ET

    Baxter International Inc. fell$. 16 or. 2 percent, to $74.04. Bristol-Myers Squibb Co. fell$. 01 or percent, to $49.09. Pfizer fell$. 01 or percent, to $28.24.

  • Final Glance: Pharmaceuticals companies Monday, 11 Aug 2014 | 6:02 PM ET

    Baxter International Inc. rose$. 30 or. 4 percent, to $74.20. Bristol-Myers Squibb Co. fell$. 10 or. 2 percent, to $49.09. Hospira rose$. 19 or. 3 percent, to $54.57.

  • Midday Glance: Pharmaceuticals companies Monday, 11 Aug 2014 | 1:26 PM ET

    Baxter International Inc. rose$. 67 or. 9 percent, to $74.57. Bristol-Myers Squibb Co. rose$. 21 or. 4 percent, to $49.40. Johnson& Johnson rose$. 21 or. 2 percent, to $101.29.

  • Aug 11- Biodel Inc said its experimental insulin formulation was found more effective than current therapies in controlling glucose after two meals, in a mid-stage trial. Type 2 diabetes patients are usually given both basal and prandial insulin in a single injection such as Humalog Mix 75/ 25, Biodel said.

  • Biodel's insulin drug found effective in trial Monday, 11 Aug 2014 | 7:30 AM ET

    Aug 11- Biodel Inc said its experimental insulin formulation was found more effective than current therapies in controlling glucose after two meals, in a mid-stage trial. The company's shares rose about 10 percent to $2.10 before the bell.

  • *Sanofi, MannKind aim to launch Afrezza in U.S. in Q1 2015. PARIS/ LONDON, Aug 11- French drugmaker Sanofi is betting on inhaled insulin as an alternative option to daily injections for diabetics by signing a worldwide licensing agreement with MannKind Corp worth up to $925 million.

  • Final Glance: Pharmaceuticals companies Friday, 8 Aug 2014 | 6:06 PM ET

    Baxter International Inc. rose$. 13 or. 2 percent, to $73.90. Bristol-Myers Squibb Co. rose$. 54 or 1.1 percent, to $49.19. Hospira rose$. 76 or 1.4 percent, to $54.38.

  • Midday Glance: Pharmaceuticals companies Friday, 8 Aug 2014 | 1:51 PM ET

    Baxter International Inc. rose$. 10 or. 1 percent, to $73.87. Bristol-Myers Squibb Co. rose$. 25 or. 5 percent, to $48.90. Hospira rose$. 31 or. 6 percent, to $53.93.

  • Early Glance: Pharmaceuticals companies Friday, 8 Aug 2014 | 10:51 AM ET

    Baxter International Inc. fell$. 38 or. 5 percent, to $73.39. Bristol-Myers Squibb Co. fell$. 11 or. 2 percent, to $48.54. Hospira fell$. 12 or. 2 percent, to $53.50.

  • *Novo expects to launch in first EU markets in H1 2015. *Shares in Novo rise 1.6 percent. Prospects for degludec- already on sale separately in Europe under the brand name Tresiba- and the new combination with Victoza are critical for Novo, which is the world's biggest insulin maker.

  • US STOCKS-Wall St flat as Caterpillar offsets Facebook Thursday, 24 Jul 2014 | 2:49 PM ET

    *Caterpillar weighs on Dow, Facebook hits record on results. NEW YORK, July 24- U.S. stocks barely budged on Thursday as corporate earnings painted a mixed picture of the economy, though the S&P 500 eked out a record intraday high for the third straight session.

  • *U.S. stocks edge up along with MSCI world index. "The lower-than-expected U.S. initial jobless claims has made people focus on the improving labor market situation," said Ian Lyngen, senior government bond strategist, at CRT Capital in Stamford, Connecticut.

  • NEW YORK, July 24- Major global stock markets edged higher while the euro rose from an eight-month low against the U.S. dollar on Thursday following upbeat euro zone data and stronger-than-expected U.S. earnings.

  • US STOCKS-Results, jobs data buoy Wall St, S&P eyes 2,000 Thursday, 24 Jul 2014 | 10:54 AM ET

    NEW YORK, July 24- The S&P 500 hit a record high for a third straight session on Thursday, lifted by jobs data and earnings, but a weak reading in new home sales kept other key stock indexes little changed.

  • July 24- Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but cost controls helped earnings beat forecasts.

  • *Facebook rallies on results; market value near IBM's. *U.S. manufacturing data due; Europe, China upbeat. NEW YORK, July 24- U.S. stock index futures rose on Thursday, following a record close on the S&P 500 index, lifted by strong job market data in the United States and overseas factory readings, while better than forecast results sent Facebook shares rallying.

  • US STOCKS-Earnings, overseas data lift futures Thursday, 24 Jul 2014 | 8:09 AM ET

    *U.S. manufacturing data due; Europe, China upbeat. NEW YORK, July 24- U.S. stock index futures rose on Thursday, following a record close on the S&P 500 index, lifted by strong data overseas and better than forecast results from Facebook.

  • UPDATE 1-Lilly beats forecasts, helped by cost controls Thursday, 24 Jul 2014 | 7:06 AM ET

    July 24- Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but earnings beat forecasts, helped by cost controls. Although revenue fell 17 percent to $4.94 billion, it topped Wall Street expectations of $4.90 billion.

  • Lilly beats forecasts, helped by cost controls Thursday, 24 Jul 2014 | 6:48 AM ET

    July 24- Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but overall results beat forecasts, helped by cost controls. The U.S. drugmaker on Thursday said it earned $734 million, or 68 cents per share, in the second quarter.

  • Politics fade as earnings take over Friday, 18 Jul 2014 | 6:30 PM ET
    Espirito Santo International is the parent company of several institutions, including Banco Espirito Santo.

    Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.